Posted by Michael Wonder on 09 Mar 2022
TGA approves provisional determination for Biocelect for COVID-19 vaccine Nuvaxovid
10 March 2022 - The TGA has granted a second provisional determination to Biocelect (on behalf of Novavax) in relation to its COVID-19 vaccine, Nuvaxovid.
Currently, Nuvaxovid is provisionally approved for the active immunisation of adults aged 18 years and older for the prevention of disease caused by SARS-CoV-2.
